reput valuat initi hold
initi coverag
initi coverag regeneron hold rate cautiou view
base belief regn solut may clinic
success commerci opportun solut might limit due
single-administr dosag potenti time market limit applic
sever patient scienc innov driven compani
promis earli stage pipelin moreov gener strong cash
flow mainli sale eylea financ clinic program eylea patent
expir loss exclus might partial off-set
product portfolio long-term potenti commerci
innov drug candid believ recent stock appreci driven
market sentiment may overreact
commercial-stag biotechnolog compani strong foundat
scientif research discoveri regn revenu domin
sale eylea expect trend continu next sever year
gener strong cash flow financ divers pipelin immunolog
oncolog infecti rare diseas
regn share rose ytd attribut investor hope
compani might treatment pandem earli data
china suggest antagonist may help lower oxygen intak
current studi patient anoth propos solut
antibodi cocktail therapi expect enter clinic earli summer
propos solut might clinic success
believ commerci opportun solut may fairli limit
sarilumab approv rheumatoid arthriti price chronic
immunolog drug would administ singl administr
patient antibodi cocktail may reach market month
howev peak demand might time
regeneron strong portfolio early-stag candid includ bi-specif
checkpoint inhibitor moreov strong perform commerci
product includ dupix libtayo help partial off-set eylea patent
expir opinion
encourag regn effort bring clinic possibl solut
pandem hold thesi base convict innov
scienc driven succeed long term short time
commerci opportun might limit
initi coverag regeneron hold rate primarili base
assess regeneron commerci opportun treatment regimen
current studi applaud manag commit deliv effect therapeut
global pandem think treatment propos regeneron may
help sever patient fight diseas
regeneron current run two program fight
trial evalu kevzara sarilumab patient hospit sever
infect sarilumab receptor antagonist current approv treat rheumatoid
arthriti ra studi base initi evid china-bas small non-
control trial anoth antagonist actemra tocilizumab appear help
lower oxygen intak hospit sever patient
novel prophylaxis/treat multi-antibodi cocktail patient yet
clinic select larg pool antibodi candid via proprietari
velocisuit antibodi technolog select process result top two antibodi
potenc bind abil spike protein idea two
protein due target differ part viru may protect multipl viral
think approach help patient might work eventu
patient sever infect describ aberr cell monocyt
activ produc larg number cytokin includ gm-csf induc
inflammatori storm cytokin storm turn may lead impair oxygen diffus
possibl pulmonari fibrosi organ failur studi run china show
preliminari evid antagonist might work think evid larg
random set need prove point
commerci perspect howev administr sarilumab limit opportun
single-tim mg administr sarilumab may result one-tim payment per
patient oppos around mg prescrib ra patient annual cours
sever year dont think revenu sarilumab success indic
would materi signific regeneron top bottom line
multi-antibodi cocktail turn expect readi clinic test earli summer
time unclear clinic result antibodi cocktail avail
estim go take month similar antibodi cocktail develop
ebola treatment yet approv fda took one year
develop clinic moreov primari endpoint ebola studi prevent death
compar standard care treatment
word multi-antibodi cocktail may take month develop
applic may limit sever patient commerci perspect though
opportun compar sarilumab price yet unclear still go
one-tim treatment dont know mani world-wide patient
month
regn stock start rise begin februari driven opinion
hope might solut pandem believ
like abl help allevi crisi commerci opportun
sarilumab antibodi cocktail somewhat limit
regn product portfolio led eylea macular degener drug gener
sustain cash flow come year opinion plan invest cash surplu
intern fuel discoveri develop innov drug wide rang
therapeut area think solid reput scientif physician
commun strong innov cultur help drive valu longer term
pandem
hold rate base belief short-term commerci opportun
might limit howev long term believ compani driven innov
cultur solid commit scienc research gener outperform market
hold rate base dcf valuat methodolog assum weight
averag cost capit wacc residu growth rate end
cash market secur current market capit
around base basic share includ regn early-stag candid
valuat analysi re-assess contribut regn valuat pipelin
key downsid risk hold rate includ clinic develop risk dupix libtayo
kevzara clinic trial expand current label clinic develop risk
includ develop risk kevzara antibodi cocktail treat addit
risk come less expect sale due higher anticip competit failur
gain support physician commun us/eu payer
upcom catalyst includ initi antibodi cocktail clinic trial updat
kevzara trial treat patient catalyst includ regulatori
submiss approv clinic updat regn drug pipelin
figur catalyst defin compani
price histori ownership
regn stock price approxim ytd vs
ibb nasdaq biotechnolog etf
think sever factor contribut regn unpreced stock price rise
ytd period appear market assum regeneron kevzara antibodi cocktail
therapi may signific impact regeneron top bottom line regn share
start diverg februari becam appar impact
us economi would substanti
current institut ownership around insid around share
top five institut holder decemb includ capit research
manag vanguard harri associ loomi sayl co none
above-ment fund appear biotech-focus invest manag notabl
insid sanofi stake figur
figur stock ownership
stock generalmarket rise nbi kevzarai believ becom treatment report ep ex-item vs factset
announc repurchas worth common stock
howev analysi show despit share repurchas basic share count
grown
think slight dilut happen due issuanc common stock award grant
long-term incent plan fact basic share count consist increas
last sever year unusu d-focus compani large-cap
pharmaceut compani often tri decreas share count increas ep case
appear concern sale ep consist grown
last sever year
share sg cog stock-bas stock-bas compens outstand addit issu price share outstand average basic option convert eopstock option warrant etc incl stock option warrant etc excl percentag dilut excl percentag dilut incl dilut share outstand dilut share outstand eop excl average fulli dilut share
commercial-stag biotechnolog compani discov develop
market medicin variou therapeut area includ ophthalmolog immunolog
oncolog cardiovascular diseas pain infecti diseas
regeneron lead product eylea solubl fusion protein act vascular endotheli
growth factor vegf inhibitor administ inject eye design block
growth new blood vessel decreas vascular permeabl eye block vegf-a
plgf two growth factor involv angiogenesi sale eylea constitut
total revenu make suscept news relat eylea commerci
legal clinic updat
sanofi collabor revenu driven collabor revenu antibodi develop
wherea bayer collabor revenu driven mostli ex-u sale eylea regeneron
profit compani debt fact regn cash market secur consist
increas last sever year model expect trend continu come
figur market secur
also expect base analysi regn public statement compani invest
cash receiv posit cash flow in-hous activ
 market seek target acquisit instead prefer invest
in-hous develop product intern
broad early-stag pipelin includ checkpoint inhibitor bi-specif antibodi
vaccin
figur bi-specif pipelin portfolio
valuat purpos howev focus late-stag candid near-term
submiss regulatori author
upcom submiss relat exist molecul
expand indic took account model progress typic life
cycl manag market biotechnolog drug also model new molecular
entiti expect file fda/ema dont think sale
molecul materi impact valuat time
import like discuss product regn pipelin kevzara
sarilumab antibodi cocktail therapi develop
pandem took begin march
interest sarilumab receptor antagonist rose anoth antagonist actemra
tocilizumab success use treat china februari took look
china-bas tocilizumab studi understand whether antagonist use covid-
tocilizumab studi china
decemb spread across china chines physician decid assess
efficaci tocilizumab sever patient one reason tocilizumab
chosen tocilizumab approv wide avail mani countri
includ china describ literatur antagonist block febril
figur china-bas studi tocilizumab
studi conduct feb feb china patient diagnos sever
critic given tocilizumab addit routin therapi within sever day
administr tocilizumab fever return normal symptom improv
remark patient lower oxygen intak one patient need
oxygen therapi ct scan show lung lesion opac absorb patient
chines scientist conclud tocilizumab effect treatment sever patient covid-
tocilizumab use new therapeut strategi treatment
opinion sever open question regard trial
non-random non-control studi small often lead ambigu
outcom larg random soc-control studi need support conclus
hard compar tocilizumab-tr patient histor control word
compar result see go us european emerg room
base data far patient mild symptom
like mani patient admit icu recov exist standard
care assum averag mortal hospit
hospit like recov
averag age patient studi year rang slightli lower
believ age typic high-risk group
safeti profil tocilizumab clear sever underli
said still believ tocilizumab may effect treatment certain covid-
patient howev think hypothesi test random set spoke
two manufactur regeneron roch compani affirm
treatment test larg trial safe administ patient
tocilizumab first approv rheumatoid arthriti ra sinc tocilizumab
receiv approv five indic bring total number indic six
interestingli tocilizumab black box warn tocilizumab administr may result
seriou infect lead hospit death includ tuberculosi bacteri viral fungal
opportunist infect word tocilizumab test ra patient
patient expos viral bacteri infect
happen administ tocilizumab patient alreadi viral infect
think one controversi open-end question
come tocilizumab treatment
anoth aspect tocilizumab ra treatment dosag drug mg/kg everi week one
recommend dose averag weight kg annual dose tocilizumab
around mg mg kg period ra chronic condit requir
on-going treatment variou medicin includ tocilizumab base data price
annual treatment ra tocilizumab around mg
figur dosag tocilizumab studi
howev treatment studi roch patient impli singl
administr tocilizumab like mg similar china-bas studi
figur dosag tocilizumab studi
revenu administr per patient like mg
less revenu earn roch ra indic importantli
potenti revenu non-repetit singl administr tocilizumab world-wide
sale across indic less
kevzara sarilumab anoth antagonist approv fairli recent market
regeneron sanofi sarilumab approv ra indic time expect
sarilumab expand label includ indic similar tocilizumab roch
hcpc codeshort descriptionhcpc code dosagepay limitvaccin awp vaccin limitblood awp blood limitclot allow limit medicar part drugseffect april june payment allow limit subject asp methodolog base asp data note absenc presenc hcpc code payment allow limit tabl indic whether medicar cover drug determin shall made local medicar contractor process claim
similar tocilizumab sarilumab black box warn risk develop seriou infect
includ viral similar tocilizumab annual recommend dosag sarilumab patient
around mg cost sarilumab similar cost tocilizumab annual
treatment sarilumab around moreov similar tocilizumab regeneron-
propos studi sarilumab impli singl administr sarilumab dose sarilumab
propos think averag dose mg
think singl administr sarilumab cost around similar case
tocilizumab sarilumab world-wide sale ra indic around
antibodi cocktail comparison ebola approach
regeneron also propos studi anoth potenti solut treatment antibodi
cocktail therapi larg pool candid regeneron select top two antibodi
cocktail treatment base potenc bind abil spike protein
regeneron took similar approach ebola viru infect howev took one
year initi complet ebola studi patient enrol notabl
primari endpoint studi prevent death ebola compar zmapp fda
still review applic regn ebola treatment approv yet
studi regeneron use velocimab technolog prepar cell line
lead antibodi select hope small quantiti avail initi
clinic test begin summer
unclear cocktail antibodi studi complet whether
success appli primari endpoint use ebola studi prevent
death might help us world diminish death associ
hospit howev studi complet whether world
high rate sever case time studi complet unknown
think commerci opportun regn antibodi cocktail rather limit given
unknown timelin outbreak antibodi cocktail studi complet
mean revenu perspect
even kevzara clinic success even help shorten icu stay believ kevzara
commerci perspect limit similar vein roch repres confirm us
tocilizumab revenu expect materi signific given limit
dosag even imagin patient administ sarilumab would result
one-tim cash flow signific market cap regeneron
anoth hand antibodi cocktail look promis commerci point view
figur anticip timelin respons
timelin cocktail avail may may coincid peak medic need
project avail treatment late summer
also unclear antibodi cocktail work prophylaxi treatment
ebola cocktail use treatment symptomat ebola patient ebola cocktail
use compar cocktail may help sever patient alreadi contract
diseas vaccin gener popul
given assumpt describ dont think solut may result
materi signific sustain revenu howev applaud team
tireless commit develop solut address current public health crisi
eylea regeneron main product global sale
us sale market regeneron ex-u sale market bayer us ex-u
sale consist grown year partial due label expans eylea includ
eylea us sale book regeneron y/i sale growth
respect expect trend continu come year
sale like neg affect pandem dont expect
demand eylea drop significantli
bayer book ex-u sale eylea book sale
us eylea sale eylea us yoy growth qoq growth row sale yoy growth
similar us sale ex-u sale grew respect next
sever year expect slightli slower pace growth eu compar growth
dupix dupilumab receptor alpha antagonist approv three indic atop
dermat asthma rhinosinus nasal polyposi
atop dermat appear drive indic dupix sale growth dupix sale
reach achiev second full year sinc launch
think sale trajectori point signific growth come year given scarciti
atop dermat treatment excel efficacy/safeti profil dupix
sanofi book sale dupix regeneron book collabor profit
dupix praluent kevzara
figur regn share collabor profit sanofi sale
despit kevzara high sale number regeneron retain profit combin sale
dupix praluent kevzara explain disconnect point lack
profit praluent kevzara side given on-going restructur regeneron/sanofi
agreement think profit figur dupix sale improv futur
libtayo cemiplimab-rwlc antibodi indic cutan squamou cell carcinoma
cscc first approv libtayo expect expand label includ oncolog
indic similar expans antibodi although magnitud expans
unclear opinion
regeneron share collabor profit reimburs develop expens incur sanofi accord regeneron payment obligation- regeneron share profit loss connect commerci share collabor profit percentag dupix praluent kevzara net product sale dupixi praluent sale
libtayo sale book regeneron libtayo impress head start sinc approv
first-full-year sale
claim libtayo grab signific market share cscc indic mostli
chemotherapi agent smaller extent opdivo keytruda opdivo keytruda
formal approv fda use cscc think partial explain
libtayo success cscc libtayo expand indic major
blockbust fda approv think significantli harder libtayo prove clinic
differenti standard care
libtayo sale libtayo yoy growth qoq growth
figur libtayo sale market share
kevzara praluent sale
kevzara approv ra around sale ra highli competit
market multipl brand agent compet indic
praluent antibodi approv hypercholesteremia disappoint sale sinc
launch us sale declin ex-u sale increas think futur
sale praluent may increas moder particularli given price competit
amgen repatha novarti inclisiran
kevzara sale sale yoy growth qoq growth sale yoy growth qoq growth sale sale yoy growth qoq growth sale yoy growth qoq growth
base recent announc restructur agreement sanofi expect gain
full us right praluent sanofi expect gain full global right kevzara
figur potenti restructur agreement sanofi
sale pipelin
number early-stag asset includ bi-specif checkpoint inhibitor
valuat purpos includ drug candid model
appropri establish either potenti sale probabl success indic
drug candid time re-assess valuat thesi program move
pivot studi and/or addit collabor revenu secur
think regn early-stag pipelin impress clinic meaning howev
assum market valu pipelin signific add-in regn approv
drug regn early-stag pipelin stand-alone compani think would trade
signific premium premium would impli possibl acquisit larg biopharma
believ pipelin sale also believ seek sale given
compani strong focu in-hous strong intern cultur long-tenur ceo who
serv sinc compani establish commit long-term growth
current depend singl product sale eylea aforement reason
think long trade sum-of-the-part discount exclud impact covid-
think fairli strong intellectu properti protect commerci stage
antibodi eylea us composit matter patent expir given expect patent
extens eylea eu patent expect expir
model eylea sale us eu keep mind patent expir biosimilar
expect eylea grow gradual lose sale due biosimilar
expect eylea grow ex-u subsequ declin
us eylea sale eylea us yoy growth qoq growth eylea row sale yoy growth
model dupix libtayo
think dupix libtayo meaning valu driver come year
assum dupix grow annual peak sale subsequ patent
expir us/eu
dupix sale book sanofi regeneron entitl collabor profit expect
dupix collabor profit reach dupix sale increas
expect libtayo grow ad addit indic oncolog
regeneron book libtayo revenu howev one import consider pay
royalti libtayo sale bm libtayo patent expir composit matter claim
expect
leonard schleifer found director presid ceo sinc
incept serv chairman board dr schleifer togeth dr
yancopoulo grown regeneron market cap compani uniqu science-
driven cultur drug discoveri develop engin capabl graduat
cornel univers earn ph pharmacolog univers virginia
dr schleifer licens physician certifi neurolog american board psychiatri
neurolog work practic neurologist found regeneron
georg yancopoulo built manag regeneron alongsid dr schleifer sinc dr
yancopoulo current presid chief scientif offic serv board sinc
dr yancopoulo along key member team princip inventor
regeneron seven fda-approv drug foundat technolog includ trap
technolog velocigen velocimmun pivot creat science-driven
collabor product cultur regeneron environ earn compani
widespread recognit includ name one innov compani
world forb magazin dr yancopoulo one highli cite scientist world
elect member nation academi scienc dr
yancopoulo attend bronx high school scienc receiv ph
dupixi sale sale yoy growth qoq growth row sale yoy growth qoq growth us libtayo sale libtayo yoy growth qoq growth
marion mccourt join regeneron serv svp head commerci
organ prior join regeneron axov clinical-stag biopharmaceut
compani presid chief oper offic serv chief oper
offic mediv acquir held commerci
leadership role includ vice-president us commerci oper vice-president gener manag
respons bone health primari care busi unit began career
spent yearsat astrazeneca ultim becom chief oper offic astrazeneca
us receiv bs lafayett colleg
robert landri execut vice presid financ chief offic
robert landri join compani serv evp financ chief offic
previous held posit svp financ chief offic previous mr landri
serv svp treasur prior posit mr landri held varieti us
intern financi gener manag posit wyeth pharmaceut
pricewaterhousecoop llp includ wyeth australian new zealand affili hold
bba account univers notr dame
david weinreich join regeneron svp late stage clinic develop medic affair
becam svp global clinic develop dr weinreich previous
svp head global develop specialti medicin bayer pharmaceut prior
bayer dr weinreich held posit increas respons focus develop
oncolog molecul dr weinreich also previous serv vice-president clinic affair gene
logic independ consult help small mid-stag biotechnolog compani
drug commerci dr weinreich receiv boston univers school
medicin mba mcdonough school busi georgetown univers bs
comput engin columbia univers
hold rate base dcf valuat methodolog assum wacc
residu growth rate expect reach peak sale
driven eylea anticip loss eylea exclus decemb
cash market secur balanc
expect continu gener posit cash flow extra cash reinvest
intern research develop valuat purpos consid relat
commerci late-stag product reflect advanc program compani
mm except per share data fy risk-adjust regeneron sale eylea-u libtayo sanofi collabor bayer collabor pipelin product risk-adjusted- total revenu collabor contract gross oper expensesresearch develop adjust research develop share-bas compens total share-bas gener administr adjust sell gener administr share-bas compens total share-bas share-bas compens exclud non- op ex sg total oper expens cog oper incom interest total non-oper incom pre-tax incom incom tax benefit tax incom unreal gain loss market unreal loss gain cash flow total comprehes incom comprehens incom basic share outstand dilut share outstand dilut share outstand eop excl ep ep
mm fy asset cash market secur account receiv trade account receiv account receiv prepaid expens current total current properti equip market defer tax non-current total liabilitiescurr liabil account accru expens current defer revenu defer revenu total current financ leas defer revenu defer revenu non-current total total stockhold total liabil
mm fy incom adjustmentsstock-bas non-cash item defer chang oper asset liabilitiesincreas sanofi bayer trade account increas increas prepaid expens increas decreas account payabl accru expens increas decreas defer flow purchas properti purchas market sale matur market flow restrict cash proce issuanc common stock payment connect common stock tender employe tax repurchas common stock- flow net increas decreas equival equival
regeneron salestot sale gener sale us eylea sale eylea us yoy growth qoq growth sale libtayo yoy growth qoq growth sale arcalyst yoy growth qoq growth
